Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

多西紫杉醇 凡德他尼 医学 内科学 肿瘤科 安慰剂 人口 肺癌 化疗 酪氨酸激酶 病理 环境卫生 受体 替代医学
作者
Roy S. Herbst,Yan Sun,Wilfried Eberhardt,Paul Germonpré,Nagahiro Saijo,Caicun Zhou,Jie Jin Wang,Longyun Li,Fairooz F. Kabbinavar,Yukito Ichinose,Shukui Qin,Li Zhang,Bonne Biesma,John V. Heymach,Peter Langmuir,Sarah M. Kennedy,H Tada,Bruce E. Johnson
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:11 (7): 619-626 被引量:388
标识
DOI:10.1016/s1470-2045(10)70132-7
摘要

Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) tyrosine kinases. In a randomised phase 2 study in patients with previously treated non-small-cell lung cancer (NSCLC), adding vandetanib 100 mg to docetaxel significantly improved progression-free survival (PFS) compared with docetaxel alone, including a longer PFS in women. These results supported investigation of the combination in this larger, definitive phase 3 trial (ZODIAC).Between May, 2006, and April, 2008, patients with locally advanced or metastatic (stage IIIB-IV) NSCLC after progression following first-line chemotherapy were randomly assigned 1:1 through a third-party interactive voice system to receive vandetanib (100 mg/day) plus docetaxel (75 mg/m(2) intravenously every 21 days; maximum six cycles) or placebo plus docetaxel. The primary objective was comparison of PFS between the two groups in the intention-to-treat population. Women were a coprimary analysis population. This study has been completed and is registered with ClinicalTrials.gov, number NCT00312377.1391 patients received vandetanib plus docetaxel (n=694 [197 women]) or placebo plus docetaxel (n=697 [224 women]). Vandetanib plus docetaxel led to a significant improvement in PFS versus placebo plus docetaxel (hazard ratio [HR] 0.79, 97.58% CI 0.70-0.90; p<0.0001); median PFS was 4.0 months in the vandetanib group versus 3.2 months in placebo group. A similar improvement in PFS with vandetanib plus docetaxel versus placebo plus docetaxel was seen in women (HR 0.79, 0.62-1.00, p=0.024); median PFS was 4.6 months in the vandetanib group versus 4.2 months in the placebo group. Among grade 3 or higher adverse events, rash (63/689 [9%] vs 7/690 [1%]), neutropenia (199/689 [29%] vs 164/690 [24%]), leukopenia (99/689 [14%] vs 77/690 [11%]), and febrile neutropenia (61/689 [9%] vs 48/690 [7%]) were more common with vandetanib plus docetaxel than with placebo plus docetaxel. The most common serious adverse event was febrile neutropenia (46/689 [7%] in the vandetanib group vs 38/690 [6%] in the placebo group).The addition of vandetanib to docetaxel provides a significant improvement in PFS in patients with advanced NSCLC after progression following first-line therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
耦23完成签到,获得积分10
刚刚
Jasper的应助被杨yang采纳,获得10
刚刚
1秒前
1秒前
2秒前
2秒前
景碧空发布了新的文献求助10
2秒前
思源的应助被俊逸季节采纳,获得10
3秒前
4秒前
蓝天的应助被胡萝卜卜采纳,获得10
4秒前
4秒前
5秒前
慕青的应助被火星上长颈鹿采纳,获得10
5秒前
樊孟完成签到,获得积分10
5秒前
许伟洋发布了新的文献求助10
5秒前
5秒前
kuxiao2333完成签到,获得积分10
6秒前
8秒前
9秒前
9秒前
9秒前
nnn发布了新的文献求助30
9秒前
9秒前
科目三的应助被日月雨辰采纳,获得10
9秒前
小兔子完成签到 ,获得积分10
10秒前
11秒前
11秒前
xunxiang完成签到,获得积分10
11秒前
FashionBoy的应助被俊逸季节采纳,获得10
11秒前
11秒前
mrwow完成签到 ,获得积分10
12秒前
12秒前
12秒前
12秒前
12秒前
kuxiao2333发布了新的文献求助10
12秒前
liusiqi完成签到,获得积分10
13秒前
13秒前
零度空间完成签到,获得积分10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8164710
求助须知:如何正确求助?哪些是违规求助? 9558507
关于积分的说明 21746304
捐赠科研通 7755421
什么是DOI,文献DOI怎么找? 3428705
关于科研通互助平台的介绍 2553143
邀请新用户注册赠送积分活动 2473218